Viking Therapeutics (VKTX) Viking Therapeutics (NASDAQ:VKTX) came out of nowhere this year to post a more than 240% gain in 2024. Wall Street analysts agree with a bullish one-year price target range.

Currently trading with a volume of 1,496,068, the VKTX's price is up by 0.83%, now at $63.27. RSI readings suggest the stock is currently may be approaching oversold. Anticipated earnings release is ...

Viking Therapeutics (VKTX) stock falls after Roche (RHHBY) posted promising Phase 1 results for its experimental obesity ...

Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Viking Therapeutics, Inc. (VKTX). Viking ...

Viking Therapeutics, Inc. (NASDAQ:VKTX): One of the Best Mid-cap Biotech Stocks to Buy Now Our Methodology For this article, ...

Viking Therapeutics' (VKTX) lead candidate for obesity, VK2735, is expected to have tremendous potential. However, existing ...

Joon Lee of Truist Financial sets a high price target of $120 for Viking Therapeutics (NASDAQ:VKTX), indicating a 72.6% ...

Jeudi, Truist Securities a maintenu une note d'achat sur Viking Therapeutics (NASDAQ:VKTX) avec un objectif de prix stable de 120,00 $. L'analyse de la firme fait suite à la publication de nouvelles d ...

Altimmune, Inc. is a biotech company exploring the potential of pemvidutide, a promising GLP-1 agonist. Click here for my ALT ...

To get the list, I screened for the following criteria: InvestorPlace - Stock Market News, Stock Advice & Trading Tips Stocks ...

Fintel reports that on May 16, 2024, Raymond James upgraded their outlook for Viking Therapeutics (NasdaqCM:VKTX) from ...

Viking Therapeutics (NASDAQ: VKTX), a clinical-stage company focused on developing novel therapeutics for metabolic and ...